HighTide Therapeutics Inc
Company Profile
Business description
HighTide Therapeutics Inc is a biopharmaceutical company specializing in the discovery, development and commercialization of multifunctional, multi-targeted therapies for the treatment of metabolic and digestive diseases. The company has developed a product pipeline of five product candidates in-house, covering nine indications in metabolic and digestive diseases among which, five are at clinical-stage. The Core Product, HTD1801 (berberine ursodeoxycholate), a new molecular entity, is a gut-liver anti-inflammatory metabolic modulator which targets multiple pathways pivotal to metabolic regulation, including those associated with metabolic and digestive diseases.
Contact
Building D, Guangdong
Floor 9 to 10, Fubao Community, Futian District
Shenzhen-Hong Kong Science and
Technology Innovation Cooperation Zone
Shenzhen518112
CHNT: +86 75526626253
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
70
Stocks News & Analysis
stocks
The best way to get rich and retire early
stocks
Investors too optimistic about ASX growth story
stocks
Stellar growth from ASX retailer but markets still too optimistic
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,095.20 | 55.10 | -0.60% |
| CAC 40 | 7,753.42 | 54.90 | 0.71% |
| DAX 40 | 24,024.78 | 56.56 | -0.23% |
| Dow JONES (US) | 44,458.61 | 483.52 | 1.10% |
| FTSE 100 | 9,147.81 | 18.10 | 0.20% |
| HKSE | 25,210.88 | 241.20 | 0.97% |
| NASDAQ | 21,681.90 | 296.50 | 1.39% |
| Nikkei 225 | 43,305.21 | 587.04 | 1.37% |
| NZX 50 Index | 12,815.58 | 55.90 | 0.44% |
| S&P 500 | 6,445.76 | 72.31 | 1.13% |
| S&P/ASX 200 | 8,818.10 | 62.70 | -0.71% |
| SSE Composite Index | 3,677.35 | 11.43 | 0.31% |